MCL1 and breast carcinoma: The functional impact of +1q, the most frequent genomic alteration in breast cancer (55–60% of patients), is more enigmatic, although some candidate drivers such as MDM4 (ref. 49), MCL1 (ref. 50), AKT3 (ref. 51) and KDM5B52 have been proposed.